Citadel Advisors’s RxSight RXST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.89M Buy
1,118,719
+72,897
+7% +$605K ﹤0.01% 3834
2025
Q4
$10.9M Sell
1,045,822
-244,322
-19% -$2.45M ﹤0.01% 3147
2025
Q3
$11.6M Buy
1,290,144
+262,281
+26% +$2.3M ﹤0.01% 3053
2025
Q2
$13.4M Buy
1,027,863
+797,642
+346% +$12M ﹤0.01% 2653
2025
Q1
$5.81M Sell
230,221
-763,946
-77% -$22.7M ﹤0.01% 3642
2024
Q4
$34.2M Buy
994,167
+782,424
+370% +$35.3M 0.01% 1622
2024
Q3
$10.5M Buy
211,743
+84,253
+66% +$4.32M ﹤0.01% 2830
2024
Q2
$7.67M Sell
127,490
-3,789
-3% -$217K ﹤0.01% 3146
2024
Q1
$6.77M Buy
131,279
+22,952
+21% +$1.13M ﹤0.01% 3499
2023
Q4
$4.37M Buy
108,327
+105,526
+3,767% +$3.1M ﹤0.01% 3998
2023
Q3
$78.1K Sell
2,801
-255,473
-99% -$7.62M ﹤0.01% 11204
2023
Q2
$7.44M Buy
258,274
+211,154
+448% +$4.7M ﹤0.01% 3072
2023
Q1
$786K Buy
47,120
+38,683
+458% +$546K ﹤0.01% 7320
2022
Q4
$107K Sell
8,437
-15,459
-65% -$188K ﹤0.01% 11122
2022
Q3
$287K Sell
23,896
-6,092
-20% -$83.7K ﹤0.01% 9679
2022
Q2
$422K Buy
+29,988
New +$396K ﹤0.01% 9044

Other funds holding RXST

Citadel Advisors's RXST Position: Q1 2026 in Review

Citadel Advisors increased its RxSight (RXST) stake by 7% in Q1 2026, buying an estimated $605K and bringing the position to 1,118,719 shares worth $6.89M. The position accounts for ﹤0.01% of the portfolio, ranked #3834.

Citadel Advisors first reported a position in RXST in Q2 2022 and has held it in 16 quarters since. The position peaked at $34.2M in Q4 2024. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

  • Citadel Advisors held 1,118,719 shares of RxSight worth $6.89M as of Q1 2026.
  • Citadel Advisors bought 72,897 RxSight shares in Q1 2026, an estimated $605K.
  • RxSight made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3834 holding.
  • Citadel Advisors first reported a position in RxSight in Q2 2022 and has held it in 16 quarters since.
  • Citadel Advisors's RxSight position peaked at $34.2M in Q4 2024.
  • 164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.